ホーム › 腎臓がん（腎細胞がん） › テキサス
テキサスにおける腎臓がん（腎細胞がん）の臨床試験
テキサス内の拠点で、腎臓がん（腎細胞がん）に関する56件の研究が参加者を募集しています。
テキサス内の都市
公式研究テキスト（英語）
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- Research Site, San Antonio
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/05更新 · NCT05536141Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
- NEO-811 Dallas Site, Dallas
- NEO-811 Houston Site, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/05更新 · NCT07300241A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- NEXT Austin, Austin
- START Center for Clinical Research, Fort Worth
- University of Texas MD Anderson Cancer Center, Houston
- 他1件
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06270706A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
- Texas Oncology, Dallas
- University of Texas Southwestern Medical Center, Dallas
- University Medical Center & Texas Tech Health Science Center, Lubbock
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06234605Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- The Don and Sybil Harrington Cancer Center, Amarillo
- UT MD Anderson Cancer Center, Houston
- Audie L Murphy VA Hospital, San Antonio
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #46, Austin
- Exelixis Clinical Site #89, Dallas
- Exelixis Clinical Site #73, Irving
- 他2件
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT05176483Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
- University of Texas - MD Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT05287945Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
- 他1件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT03866382Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
- UT MD Anderson Cancer Center, Houston
被験者募集中第2相
12歳以上 · 全性別 · 2026/09/29更新 · NCT04981509REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07594106Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Baylor, Scott and White Research Institute, Dallas
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06047379Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Texas Oncology (Balcones) - SCRI, Austin
- MD Anderson Cancer Center, Houston
- START South Texas Accelerated Research Therapeutics, San Antonio
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/18更新 · NCT05267626A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
- M D Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/18更新 · NCT05048212Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- 他3件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/18更新 · NCT05327686Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
- Texas Oncology - Central South, Austin
- Texas Oncology - Central South, Austin
- Texas Oncology - Central South, Austin
- 他26件
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07227415Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus
- University of Texas Southwestern Medical Center, Dallas
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT05319015TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/15更新 · NCT04969315A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
- Md Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/15更新 · NCT07195916ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- UT Southwestern Medical Center, Dallas
- DHR Health Advance Care Center, Edinburg
- The Center for Cancer and Blood Disorders, Forth Worth
- 他1件
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/14更新 · NCT05059444Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
- Mary Crowley Cancer Research, Dallas
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/09更新 · NCT06750185Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
- The Don and Sybil Harrington Cancer Center, Amarillo
- Houston Methodist San Jacinto Hospital, Baytown
- Houston Methodist Cypress Hospital, Cypress
- 他13件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/02更新 · NCT06661720Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- START San Antonio, San Antonio
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/27更新 · NCT06582017Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
- MD Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/20更新 · NCT06940518Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
- The University of Texas M. D. Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/20更新 · NCT07187778A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Research Site, Houston
- Research Site, San Antonio
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/19更新 · NCT07115043Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
- University of Texas, Southwestern Medical Center, Dallas
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/19更新 · NCT05361720Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
- NEXT Oncology, Austin, Austin
- NEXT Oncology, San Antonio, San Antonio
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/18更新 · NCT06966024A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Houston Methodist Hospital, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/17更新 · NCT04895709A Study of MGC026 in Participants With Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/11更新 · NCT06242470A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
- START San Antonio, San Antonio
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/11更新 · NCT07195682Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study
- The University of Texas M. D. Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/11更新 · NCT07187869A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, San Antonio
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/06更新 · NCT07749586IDOV-Immune for Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics, San Antonio
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/05更新 · NCT06910657PET/MR for Characterization of Renal Masses (RMs)
- University of Texas Southwestern Medical Center, Dallas
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中観察研究
18歳以上 · 全性別 · 2026/08/04更新 · NCT06076538Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
- MD Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/30更新 · NCT05663710Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- The University of Texas Health Science Center at Tyler, Tyler
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/29更新 · NCT04198766Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma
- UT MD Anderson, Houston
被験者募集中第1相
18歳〜70歳 · 全性別 · 2026/07/29更新 · NCT07564232Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
- M D Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/16更新 · NCT05092373A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- MD Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/09更新 · NCT03972657ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。